Compare iShares China Large-Cap ETF (FXI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Novo Nordisk A/S — how do they compare? iShares China Large-Cap ETF trades at $34.54, while Novo Nordisk A/S trades at $50.65 (market cap $222.24B). The key difference: Novo Nordisk A/S pays a 3.56% dividend while iShares China Large-Cap ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | NVO | |
|---|---|---|
52-Week High | $41.75 | $71.70 |
52-Week Low | $31.59 | $35.29 |
Market Cap | — | $222.24B |
Sector | — | Health |
Enterprise Value | — | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI is currently trading at $34.545, up 2.29% with strong technical momentum indicated by bullish moving averages and ADX signals. The ETF benefits from China's accelerating AI and manufacturing sectors, with recent news highlighting a $295 billion AI infrastructure plan and robust export growth. However, RSI readings above 89 suggest the ETF is significantly overbought near-term.
The outlook remains positive given China's strategic investments in technology and manufacturing, though investors face risks from US-China trade tensions and potential profit-taking after recent gains. Wall Street sentiment is cautiously optimistic as institutional flows respond to China's economic initiatives.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
